Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy

[1]  A. Tanskanen,et al.  Healthcare utilization, costs, and productivity losses in treatment-resistant depression in Finland – a matched cohort study , 2022, BMC Psychiatry.

[2]  A. Sauvaget,et al.  Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme , 2022, International journal of psychiatry in clinical practice.

[3]  M. Drummond,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. , 2022, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[4]  M. Leboyer,et al.  A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials , 2021, Molecular Psychiatry.

[5]  C. Kerr,et al.  Health-related quality of life burden associated with treatment-resistant depression in UK patients: Quantitative results from a mixed-methods non-interventional study. , 2021, Journal of affective disorders.

[6]  S. Pype,et al.  Real-World Treatment Patterns, Outcomes, Resource Utilization and Costs in Treatment-Resistant Major Depressive Disorder: PATTERN, a Retrospective Cohort Study in Belgium , 2021, PharmacoEconomics - Open.

[7]  M. Roca,et al.  Economic impact of treatment-resistant depression: A retrospective observational study. , 2021, Journal of Affective Disorders.

[8]  C. Mencacci,et al.  The costs of treatment resistant depression: evidence from a survey among Italian patients , 2021, Expert review of pharmacoeconomics & outcomes research.

[9]  G. Maina,et al.  Healthcare Resource Consumption and Related Costs of Patients Estimated with Treatment-Resistant Depression in Italy , 2021, ClinicoEconomics and outcomes research : CEOR.

[10]  C. Otte,et al.  Real-world evidence from a European cohort study of patients with treatment resistant depression: Baseline patient characteristics. , 2020, Journal of affective disorders.

[11]  C. Demuro,et al.  Self-reported review of the value of esketamine in patients with treatment-resistant depression: Understanding the patient experience in the STRIVE Study , 2020, Psychiatry Research.

[12]  D. Soeteman,et al.  Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States. , 2020, Psychiatric services.

[13]  A. Young,et al.  Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). , 2020, The Journal of clinical psychiatry.

[14]  W. Drevets,et al.  Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. , 2019, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[15]  Xiang Li,et al.  Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. , 2019, JAMA psychiatry.

[16]  M. Fava,et al.  Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) , 2019, The international journal of neuropsychopharmacology.

[17]  R. Shelton,et al.  Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. , 2019, The American journal of psychiatry.

[18]  J. Sheehan,et al.  PMH19 COST-EFFECTIVENESS ANALYSIS OF ESKETAMINE IN TREATMENT-RESISTANT DEPRESSION IN THE UNITED STATES , 2019, Value in Health.

[19]  O. Andreassen,et al.  The Promise of Intranasal Esketamine as a Novel and Effective Antidepressant. , 2017, JAMA psychiatry.

[20]  Praveen Thokala,et al.  Cost-Effectiveness Thresholds: the Past, the Present and the Future , 2018, PharmacoEconomics.

[21]  T. Suppes,et al.  Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Major Depressive Disorder. , 2017, The Journal of clinical psychiatry.

[22]  Daniel J. Müller,et al.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder , 2016, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[23]  Pedro Serrano-Aguilar,et al.  On the Estimation of the Cost-Effectiveness Threshold: Why, What, How? , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[24]  Katherine E. Watkins,et al.  The American Psychiatric Association Practice Guidelines for the Psychiatric Evaluation of Adults , 2015 .

[25]  Kyung-Yeol Bae,et al.  Comorbidity of Depression with Physical Disorders: Research and Clinical Implications , 2015, Chonnam medical journal.

[26]  Pim Cuijpers,et al.  Comprehensive meta-analysis of excess mortality in depression in the general community versus patients with specific illnesses. , 2014, The American journal of psychiatry.

[27]  Giancarlo Cesana,et al.  Italian population-based values of EQ-5D health states. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[28]  N. Olchanski,et al.  The economic burden of treatment-resistant depression. , 2013, Clinical therapeutics.

[29]  David Moher,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[30]  K. S. Al-Harbi.  Treatment-resistant depression: therapeutic trends, challenges, and future directions , 2012, Patient preference and adherence.

[31]  C. Hollenbeak,et al.  Rates and Probabilities in Economic Modelling , 2012, PharmacoEconomics.

[32]  M. Porter.  A strategy for health care reform--toward a value-based system. , 2009, The New England journal of medicine.

[33]  G. Fattore.  Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia , 2009 .

[34]  M. Fava,et al.  The STAR*D study: Treating depression in the real world INTERPRETING KEY TRIALS , 2007 .

[35]  W. Alexander.  American psychiatric association. , 2008, P & T : a peer-reviewed journal for formulary management.

[36]  Julien Mendlewicz,et al.  Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. , 2007, The Journal of clinical psychiatry.

[37]  C. Hollenbeak,et al.  Rates and probabilities in economic modelling: transformation, translation and appropriate application. , 2007, PharmacoEconomics.

[38]  D. Kupfer,et al.  Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report , 2006 .

[39]  Michaël Lauer,et al.  Book Review Redefining Health Care: Creating Value-Based Competition on Results By Michael E. Porter and Elizabeth Olmsted Teisberg. 506 pp. Boston, Harvard Business School Press, 2006. $35. 978-1-59139-778-6 , 2006 .

[40]  B. Santarlasci,et al.  Guadagno di sopravvivenza dei nuovi farmaci , 2004 .

[41]  王德伦,et al.  英语-翻译-Internet , 2000 .

[42]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.